<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637442</url>
  </required_header>
  <id_info>
    <org_study_id>University Bonn</org_study_id>
    <nct_id>NCT00637442</nct_id>
  </id_info>
  <brief_title>Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)</brief_title>
  <acronym>CASL-AD-01</acronym>
  <official_title>Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal Ministry of Health, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examination of the correlation between the cerebral bloodflow and the clinical change under
      treatment with Reminyl retard® and the prediction of clinical change by measuring the
      cerebral bloodflow in patients with mild to moderate Alzheimer's Disease
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral perfusion</measure>
    <time_frame>baseline and after 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog)</measure>
    <time_frame>baseline, after 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Functional Assessment and Change Scale (ADFACS)</measure>
    <time_frame>baseline, after 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>baseline, after 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental-Status-Examination (MMSE)</measure>
    <time_frame>baseline, after 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>CASL-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reminyl retard</intervention_name>
    <description>retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg</description>
    <arm_group_label>CASL-MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA

          -  Underwritten study consent

          -  No treatment with acetylcholinesterase inhibitors

          -  Mini-Mental-State Examination: 12-25 points

          -  Age: 50-80 Years

          -  Orale contraception for women of child-bearing age

        Exclusion Criteria:

          -  Mental Disorders

          -  Other Diseases of the CNS

          -  Severe Illness

          -  Contraindication for MRI-Scan

          -  Contraindication for Galantamin (Reminyl retard®)

          -  Participation at other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Jessen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>November 8, 2010</last_update_submitted>
  <last_update_submitted_qc>November 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Frank Jessen, MD</name_title>
    <organization>University Hospital, Bonn</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

